Psyence Biomed Enters Into $25M Common Stock Purchase Agreement With White Lion Capital
Portfolio Pulse from Benzinga Newsdesk
Psyence Biomed Ltd. (NASDAQ:PBM) has entered into a $25 million common stock purchase agreement with White Lion Capital, allowing the company to sell up to $25 million in shares over 24 months, subject to SEC conditions.
July 31, 2024 | 8:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Psyence Biomed Ltd. (NASDAQ:PBM) has entered into a $25 million common stock purchase agreement with White Lion Capital, allowing the company to sell up to $25 million in shares over 24 months, subject to SEC conditions.
The agreement provides Psyence Biomed with a significant potential capital infusion, which can be used for growth and operational needs. The flexibility in the purchase agreement terms and the lack of upper price limits are positive indicators for the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100